IRLAB Therapeutics: Signs evaluation agreement with MSRD - ABG

IRLAB and MSRD sign agreement to evaluate IRL757 & IRL942
Successful evaluation may lead to collaboration on development
A future collaboration could reduce capital needs


IRLAB enters agreement with Otsuka's R&D centre MSRD

Today, IRLAB announced entering into a strategic R&D agreement with Otsuka's McQuade Centre for Strategic Research and Development, LCC (MSRD). Under the agreement, MSRD will carry out a preclinical evaluation of IRLAB's drug candidates IRL757 and IRL942. After this, MSRD and IRLAB may agree to further collaborate on the development of the two drugs moving forward. The MSRD was established by Otsuka to identify and fund new early stage R&D programmes that have the potential to be part of Otsuka's pipeline. The agreement has provided an undisclosed upfront payment, but we do not consider it to be a significant sum.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2023/5/irlab-therapeutics---signs-evaluation-agreement-with-msrd/